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Introduction
In the last decade, treatment of elevated lipid concentrations has been fundamentally changed by the introduction of the hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors or statins. As the use of these agents has been proven to be effective and safe in adults, they might also be beneficial for hypercholesterolemic children.
The most important target paediatric population for lipid reduction includes children with homozygous or heterozygous familial hypercholesterolemia (FH). FH is an autosomal dominantly inherited metabolic disease , due to mutations in the LDL receptor (LDLR) gene 2 . FH is clinically characterized by elevated levels of low-density lipoprotein cholesterol (LDL-C) and total cholesterol (TC) from birth onwards resulting in early atherogenesis and premature cardiovascular disease (CVD).
The urgent need for early therapy in children with heterozygous FH has been substantiated by studies using surrogate markers which are able to assess subclinical atherosclerosis and thereby predict cardiovascular disease. As the early stages of the process of atherosclerosis are characterized by endothelial dysfunction and intima media thickening, widely used surrogate markers to assess preclinical atherosclerosis are flow-mediated dilatation (FMD), which measures endothelial function of the brachial artery, and B-mode ultrasound, which measures the intima-media thickness (IMT) of the carotids and the femoral arteries. In recent years, several studies have unequivocally shown that endothelial function measured as FMD of the brachial artery is impaired'" and carotid IMT is increased " in FH children when they are compared to healthy controls. This underscores the very early onset of atherogenesis in FH children and the need for early and aggressive treatment.
Currently, the recommended therapy for hypercholesterolemic children only consists of dietary and life-style modifications. The National Cholesterol Education Program (NCEP) recommends considering drug therapy in children aged 10 years and older if, after an adequate
Step II diet, they still have LDL-C levels >190 mg/dl (4.9 mmol/L) or >160 mg/dl (4.1 mmol/L) in the presence of a positive family history for premature CVD (before 55 years of age) . In this article we describe the spectrum of statin therapy in children with hypercholesterolemia in terms of efficacy, safety, pharmacokinetics and psychosocial functioning.
Efficacy
Effects of various statins on lipids and lipoproteins in FH children Table 1 presents an overview of studies that have been conducted with statins in children and adolescents. All trials demonstrated significant reductions in the levels of LDL-C, TC, and apolipoprotein B100 (apoB). The reduction of LDL-C levels varied between 17 and 45%, for TC between 13 and 37%, and for apoB between 18 and 1 7-77 34%, depending on dose and statin used in the trial " . Most studies demonstrated mean elevations of HDL-cholesterol (HDL-C) levels between 1 and 11% and of apoAI between 2 and 10% in the statin treated children, but these differences were not statistically significant as compared to either placebo or baseline. One study showed a significant increase in HDL-C of 22.5% after treatment with atorvastatin, but this study was not controlled" . Table 2 gives an overview of the efficacy of various statins in children.
Overall, all studies demonstrated that statins are efficacious in terms of lowering LDL-C levels in children who are at high risk for premature CVD The changes are the means of the changes of the various studies, per statin. f children younger than 14 years received 20 mg, and those 14 years and older received 40 mg pravastatin. The study of Ducobu et al was not included as the lipid changes of the three dosages could not be disentangled. § We did not include atorvastatin 40 mg 24 because only two children were treated with this medication. 11 The reductions are presented as the percentage reduction as compared to the diet intervention. 55% of the patients in the atorvastatin treatment group received 20 mg and 45% received 10 mg atorvastatin abnormalities of the arterial wall after the use of statins highlights the importance of early initiation of such therapy in children with rapidly progressive atherosclerosis such as FH heterozygotes.
I is However, myalgia without changes in creatine phosphokinase (CK) is often a reason to change statin therapy in adults.
All above-mentioned side effects have also been reported in the statin studies with children, but adverse events, whether or not judged to be related to therapy, did not differ between treatment and placebo groups ' ' ' ' . However, some adverse effects resulted in discontinuation of the study subjects. With respect to the liver enzymes alanine aminotransferase (ALT) and aspartate aminotransferase (AST), some trials showed increased levels in the active treatment group as compared to the placebo group. In the simvastatin study of de Jongh et al, one child experienced several elevations <3x ULN as well as one elevation >3x ULN.
Those elevations were considered drug related but not clinically significant. Therapy was interrupted for ten days, and levels returned to normal . In the study of McCrindle et al, two children treated with atorvastatin (10 20 mg) had an AST elevation of >3x ULN and one had an ALT elevation of >3x ULN, whereas no placebo-treated patients had such elevations. However, none of the children discontinued the study medication .
In an uncontrolled study of Lambert et al, statistically significant but minor and clinicallv unimportant increases of 2 and 3x U/L from baseline were observed in AST levels during treatment with 30-and 40 mg lovastatin, respectively. ALT levels were not changed . In other controlled studies, there were no differences between the statin
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and the placebo group with respect to liver enzyme changes '
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In summary, discontinuation of statin treatment due to hepatic transaminase or CK elevation was rare in the total number of 665 paediatric patients who received statins for 6 to 156 weeks. In most cases, such elevations decreased to normal spontaneously without changing or interrupting the study medication.
Hormone levels, growth and sexual maturation synthesis, an increase of steroid hormones levels was totally unexpected and could not be explained by the investigators. In the case of simvastatin, the decrease of DHEAS was small and investigators did not observe a deviation in growth nor sexual development.
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Therefore, no clinical significance was attributed to the effects on DHEAS . In contrast, in the pravastatin trial no changes were found in the levels of DHEAS ~. Furthermore, statins did neither affect the gonadal hormone estradiol in girls or testosterone in boys, nor 21 23 the gonadotropic hormones lutropin and follicle-stimulating hormone (FSH) ' ".
Besides a slight progression to more advanced Tanner staging and larger testicular volume in the lovastatin group at rates not significantly different from those of the placebo group , no deviations were observed for sexual maturation or growth in any other study .
In conclusion, statins do not appear to have clinically meaningful effects on hormone levels, growth or sexual maturation in children.
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Pharmacokinetics of statin therapy in children
The pharmacokinetics of statins have been widely studied in adults' . In order to formulate a rational dosing regimen for children, such studies have to be conducted in children as well. In fact, two trials have described the single-dose pharmacokinetics of pravastatin in children; one with a single dose of 10 mg pravastatin in 20 children with In view of the lack of adverse effects of statins in children with FH, we must conclude that statin therapy seems safe. All studies reported some adverse effects, but these were equally distributed between the placebo and statin groups. The investigators reported no cases of myositis, myopathy or rhabdomyolysis. Besides one hospitalization for a child with worsening of depression during atorvastatin administration, none of the investigators reported any serious adverse event or death with the use of statins in children. With respect to routine laboratory parameters some studies reported increased liver enzymes and CK levels without clinical symptoms. These laboratory abnormalities returned to normal without removal of the study drug. No serious adverse effects, in terms of laboratory abnormalities were reported in these children. Even though several trials demonstrated significantly increases or decreases in DHEAS during statin use in the pubertal children, those changes were not clinicallv relevant. Taken together, statins seem safe not only for adults, but also for hypercholesterolemic children.
We need to point out that children were not followed for more than 2 years of statin treatment. Therefore, no guarantee can be given that statins are safe for life-long use.
Follow-up studies are required to assess this. Long-term follow-up studies are also required to investigate whether statin therapy at a young age prevents premature CVD at an older age.
It is still unclear at what age statin therapy should be considered. The age of the youngest patients in the studies varied from 4-10 years (table 1) , which indicates that patients can be safely treated at an age of 10 years. However, further research is needed to determine if statin therapy should be initiated at a younger age.
If children have started with statin therapy, they should be seen by a lipid specialist or pediatrician at regular intervals. Growth, sexual development, and liver enzymes levels should be checked frequently. Because statins increase the risk for myopathy or rhabdomyolysis, CK levels should be evaluated as well. Patients and their families should be instructed to immediately report symptom of muscle pain, myalgia, weakness, or the appearance of dark urine. In such case, CK levels should be assessed, and if levels are more than 5 times of normal, therapy should be discontinued. If CK levels have returned to normal, therapy may be continued at a lower dose. Furthermore, limited evidence from animal and human studies indicates that statins should not be taken during pregnancy . Adolescent girls and young women taking statins should be counseled about the need for contraception.
In conclusion, statins seem safe and are proven to be effective to lower cholesterol concentrations in prepubertal and post-pubertal children. Early initiation of statin therapy seems to be the proper therapeutic option with regards to improvement of endothelial dysfunction, regression of intima-media thickening, and prevention of future cardiovascular events.
